Advertisement
Advertisement
ADPT
Adaptive Biotechnologies Corporation Common Stock
14.68
USDSponsored
+0.41
+2.89%
May 04, 10:58 UTC -4
Open
ADPT Earnings Reports
Positive Surprise Ratio
ADPT beat 22 of 27 last estimates.
81%
Next Report
Tomorrow AMC
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$62.07M
/-$0.16
Implied change from Q4 25 (Revenue/ EPS)
-13.41%
/+77.78%
Implied change from Q1 25 (Revenue/ EPS)
+18.35%
/-20.00%
Adaptive Biotechnologies Corporation Common Stock earnings per share and revenue
On Feb 05, 2026, ADPT reported earnings of -0.09 USD per share (EPS) for Q4 25, beating the estimate of -0.18 USD, resulting in a 51.33% surprise. Revenue reached 71.68 million, compared to an expected 60.58 million, with a 18.33% difference. The market reacted with a -1.04% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.16 USD, with revenue projected to reach 62.07 million USD, implying an increase of 77.78% EPS, and decrease of -13.41% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Axsome Therapeutics, Inc
Report Date
May 04, 2026 For Q1 26
Estimate
-$0.91
Actual
-$1.26
Surprise
-37.96%
Krystal Biotech, Inc. Common Stock
Report Date
May 04, 2026 For Q1 26
Estimate
$1.44
Actual
$1.83
Surprise
+26.33%
Kymera Therapeutics, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.89
Actual
-$0.71
Surprise
+21.05%
Twist Bioscience Corporation Common Stock
Report Date
May 04, 2026 For Q2 26
Estimate
-$0.48
Actual
-$0.62
Surprise
-27.34%
Amgen Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$4.85
Actual
$5.15
Surprise
+6.14%
Moderna, Inc. Common Stock
Report Date
May 01, 2026 For Q1 26
Estimate
-$4.04
Actual
-$3.40
Surprise
+15.85%
DBV Technologies S.A.
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.08
Actual
-$0.11
Surprise
-36.14%
ADC Therapeutics SA
Report Date
May 04, 2026 For Q1 26
Estimate
-$0.21
Actual
-$0.21
Surprise
+4.24%
Emergent Biosolutions, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.25
Actual
$0.21
Surprise
+183.17%
Barinthus Biotherapeutics plc - ADR
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.28
Actual
-$0.14
Surprise
+50.98%
FAQ
What were Adaptive Biotechnologies Corporation Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Adaptive Biotechnologies Corporation Common Stock reported EPS of -$0.09, beating estimates by 51.33%, and revenue of $71.68M, 18.33% above expectations.
How did the market react to Adaptive Biotechnologies Corporation Common Stock's Q4 2025 earnings?
The stock price moved down -1.04%, changed from $18.26 before the earnings release to $18.07 the day after.
When is Adaptive Biotechnologies Corporation Common Stock expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Adaptive Biotechnologies Corporation Common Stock's next earnings report?
Based on 10
analysts, Adaptive Biotechnologies Corporation Common Stock is expected to report EPS of -$0.16 and revenue of $62.07M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement